

COUNTRY GENERAL INFORMATION (WHO, 2015)

Total population:	188,925,000
Gender F / M (%):	47.2 / 52.9
Population, age group <15/≥15 years (%):	34 / 66
Life expectancy at birth (F/M, years) (2015):	68 / 66
GDP (PPP int \$):	4,790
Income status:	Lower middle
Number of 2 nd sub-national administrative level divisions, name:	149, District

EPIDEMIOLOGY

	VL	CL ^{a,b}	PKDL	MCL
Endemicity status:	Endemic	Endemic	Non endemic	Non endemic
Number of new cases (incidence):	No data	No data	N/A	N/A
Number of relapses ¹ :	No data	No data	N/A	N/A
Total number of cases:	0	16,648	N/A	N/A
Imported cases (#, %):	No data	No data	N/A	N/A
Gender distribution (% F):	No data	No data	N/A	N/A
Age group distribution (% <5/5-14/>14):	No data	No data	N/A	N/A
Incidence rate (cases/10,000 population in endemic areas):	No data	0.33	N/A	N/A
Number of endemic 2 nd sub-national administrative level divisions:	No data	No data	N/A	N/A
Population at risk ² (% # at risk/total population):	No data	No data	N/A	N/A
Was there any outbreak?	No data	No data	N/A	N/A
Number of new ³ foci:	No data	No data	N/A	N/A


N/A = Not applicable; ¹ Relapse in this country is defined as: No definition available; ² Defined as "Number of people living in 2nd sub-national administrative level endemic areas"; ³ Defined as "In this reporting period, an area at the 2nd sub-national administrative level reporting cases for the first time ever"; ^a In Pakistan, both ACL (anthroponotic cutaneous leishmaniasis) and ZCL (zoonotic cutaneous leishmaniasis) are endemic but information was only available as aggregated "cutaneous leishmaniasis"; ^b only partial data available for 2015 (from Khyber Pakhtunkhwa and FATA provinces).

Monthly distribution of new cases (January-December)


2015	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	No data	No data	No data	No data	No data	No data	No data	No data	No data	No data	No data	No data
CL	No data	No data	No data	No data	No data	No data	No data	No data	No data	No data	No data	No data

VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL = post-kala-azar dermal leishmaniasis; MCL = mucocutaneous leishmaniasis

Visceral leishmaniasis




Cutaneous leishmaniasis




Incidence rate/10,000 (at the national level) and number of new cases from 1998 to 2015

Visceral leishmaniasis



Cutaneous leishmaniasis



Disease distribution of new VL and CL cases

No data under national level

CONTROL AND SURVEILLANCE

Year Leishmaniasis National Control Programme (LNCP) was established:	Not available
Type of surveillance:	Other
Is there a vector control programme?	No
Type of insecticide used for Indoor residual Spraying (IRS):	Deltamethrin
Year latest national guidelines:	2002
Is leishmaniasis notifiable (mandatory report)?	No
Is there a reservoir host control programme?	No
Number of leishmaniasis health facilities:	Not available

DIAGNOSIS

	VL	CL	PKDL	MCL
Number of people screened actively for:	No data	No data	N/A	N/A
Number of people screened passively for:	No data	No data	N/A	N/A
Cases diagnosed by RDT (% , # RDT+ / total VL cases):	No data	N/A	N/A	N/A
Proportion of positive RDT (% , # RDT+ / total RDT):	No data	N/A	N/A	N/A
Cases diagnosed by direct exam* (parasitology) (% , # slides + / total cases):	No data	No data	N/A	N/A
Proportion of positive slides (% , # slides + / total slides):	No data	No data	N/A	N/A
Cases diagnosed clinically (% , # clinical cases / total cases):	No data	No data	N/A	N/A
Proportion of CL cases with lesions equal to or greater than 4 cm:	N/A	No data	N/A	N/A
Proportion of CL cases with 4 or more lesions (% , # CL cases / total CL cases):	N/A	No data	N/A	N/A
Percentage of cases with HIV coinfection:	No data	N/A	N/A	N/A

N/A = Not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus

TREATMENT AND MEDICINES

- ▶ Is treatment provided for free in the public sector? **No**
- ▶ Antileishmanial medicines included in the National Medicine List: **None**

TREATMENT OUTCOME

	VL	CL
Proportion of cases treated (% , # treated cases / total cases):	No data	No data
Initial cure rate(% , # cases initially cured / total cases):	No data	No data
Failure rate ⁴ (% , # patients with treatment failure / total cases):	No data	No data
Case fatality rate (% , # patients who died / total cases):	No data	No data

VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL= post-kala-azar dermal leishmaniasis; MCL = mucocutaneous leishmaniasis

⁴ Failure in this country is defined as: No definition available